News
GYRE
15.02
+0.27%
0.04
Weekly Report: what happened at GYRE last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at GYRE last week (0708-0712)?
Weekly Report · 07/15 09:58
Weekly Report: what happened at GYRE last week (0701-0705)?
Weekly Report · 07/08 09:59
Gyre Therapeutics Seeks Compliance Amid Board Reshuffle
TipRanks · 07/05 21:18
Gyre Therapeutics Gets China's Approval For Tablets For Thrombocytopenia Treatment
NASDAQ · 07/02 20:54
Gyre Wins China Approval for Tablet to Treat Thrombocytopenia
Dow Jones · 07/02 20:32
GYRE THERAPEUTICS ANNOUNCES CHINA’S NMPA APPROVAL OF AVATROMBOPAG MALEATE TABLETS FOR THE TREATMENT OF CLD-ASSOCIATED THROMBOCYTOPENIA
Reuters · 07/02 20:05
Weekly Report: what happened at GYRE last week (0624-0628)?
Weekly Report · 07/01 10:00
Weekly Report: what happened at GYRE last week (0617-0621)?
Weekly Report · 06/24 10:03
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
Gyre Therapeutics is a clinical-stage biotechnology company developing anti-fibrotic therapeutics for chronic organ diseases. The company's hydronidone has been published in the Journal of Gastroenterology and Hepatology. Studies support the potential of the drug as a promising therapy for the treatment of liver fibrosis.
Barchart · 06/18 15:05
Weekly Report: what happened at GYRE last week (0610-0614)?
Weekly Report · 06/17 09:59
Weekly Report: what happened at GYRE last week (0603-0607)?
Weekly Report · 06/10 10:00
Weekly Report: what happened at GYRE last week (0527-0531)?
Weekly Report · 06/03 10:01
Week In Review: MediLink And BioNTech Form $1.8B ADC Partnership
Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform. Asahi Kasei offers $1.1 billion to acquire Calliditas Therapeutics of Sweden. Suzhou CStone Pharma is selling marketing rights for its lead drug to Switzerland's Ewopharma. Bayer and China's Burning Rock Biotech collaborate to develop companion diagnostic products. Medi Link and BioNTECH form $1,8B ADC Partnership.
Seeking Alpha · 06/02 07:00
Gyre Therapeutics Advances with F230 IND Approval in China
TipRanks · 05/30 21:22
Gyre Pharmaceuticals Receives IND Approval From Center For Drug Evaluation Of China's NMPA To Evaluate F230 For The Treatment Of Pulmonary Arterial Hypertension
China's National Medical Products Administration has approved Gyre Pharmaceuticals' application for F230 tablets for the treatment of pulmonary arterial hypertension. F230 is a selective endothelin receptor antagonist. Gyre is a clinical-stage biotechnology company developing anti-fibrotic therapeutics.
Benzinga · 05/30 20:37
GYRE THERAPEUTICS INC: RECEIVES IND APPROVAL FROM CHINA'S NMPA TO EVALUATE F230 FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
Reuters · 05/30 20:25
Gyre Therapeutics files to sell 1.08M shares of common stock for holders
Healthcare Gyre Therapeutics files to sell shares of common stock for holders May 30, 2024. The company filed a prospectus related to the offer and resale of up to 1,081,332 shares of stock. This prospectus is not an offer to sell.
Seeking Alpha · 05/30 20:17
GYRE THERAPEUTICS FILES FOR MIXED SHELF OFFERING FOR $150 MLN - SEC FILING
Reuters · 05/30 20:08
GYRE THERAPEUTICS INC FILES FOR SHELF OF UP TO 1.1 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING
Reuters · 05/30 20:05
More
Webull provides a variety of real-time GYRE stock news. You can receive the latest news about Gyre Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About GYRE
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.